Comparative review of third-generation progestins.
Desogestrel, gestodene, and norgestimate represent a new generation of progestins designed for use in oral contraceptives. A high degree of efficacy has been retained in these progestins, and the adverse metabolic impact exhibited by older progestins has been reduced considerably. The clinical profile of each progestin, as it is marketed in Europe in combination with ethinyl estradiol, is reviewed. Direct comparisons are made whenever applicable. The major advantages of these formulations over the older combined oral contraceptives are that they have less effect on lipid metabolism and on carbohydrate metabolism, and they are less androgenic. The clinical implications of these findings are discussed.
R.W. Johnson Pharmaceutical Research Institute, Raritan, New Jersey.
M E
ME
Kafrissen
S L
SL
Corson
D003276:Contraceptives, Oral / Q000592:standards*; D017135:Desogestrel; D005260:Female; D006801:Humans; D009644:Norgestrel / Q000031:analogs & derivatives* / Q000592:standards; D009652:Norpregnenes / Q000592:standards*
D003276:Contraceptives, Oral; D009652:Norpregnenes; C033273:Gestodene; D009644:Norgestrel; D017135:Desogestrel; C017576:norgestimate